Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Stoke Therapeutics ( (STOK) ) is now available.
On January 21, 2026, Stoke Therapeutics, Inc. signed a long-term lease for a new corporate headquarters and laboratory at 245 Fifth Avenue in Waltham, Massachusetts, expanding its facilities to approximately 98,500 square feet. The lease runs through March 31, 2038, with two five-year extension options at market rates, and carries an estimated $85.5 million in base rent over its term plus a $3 million security deposit via standby letter of credit, underscoring the company’s commitment to scaling its operations and supporting future growth in its research and development footprint.
The most recent analyst rating on (STOK) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.
Spark’s Take on STOK Stock
According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.
The score is driven mainly by improving financial performance (profitability turning positive and a strong, low-leverage balance sheet) and supportive technical uptrend signals. These positives are tempered by expensive valuation (P/E 51) and lingering cash flow volatility, while recent corporate updates add a modest positive catalyst.
To see Spark’s full report on STOK stock, click here.
More about Stoke Therapeutics
Stoke Therapeutics, Inc. is a biotechnology company focused on developing RNA-based medicines, with operations that require significant office and laboratory space to support its research and development activities.
Average Trading Volume: 963,412
Technical Sentiment Signal: Buy
Current Market Cap: $1.68B
See more data about STOK stock on TipRanks’ Stock Analysis page.